Cover Image
市場調查報告書

角膜潰瘍:開發平台分析

Corneal Ulcers - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 321932
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
角膜潰瘍:開發平台分析 Corneal Ulcers - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 37 Pages
簡介

角膜潰瘍是角膜的潰瘍,有眼睛發癢、淚眼、眼皮腫、視力降低、對光過敏等症狀。危險因子有氣候條件、免疫力低落、發炎性障礙、眼球損傷、缺乏維他命A等。治療方法有角膜移植,使用皮質類固醇眼科用藥等。

本報告提供角膜潰瘍的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

角膜潰瘍概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

開發治療藥的企業

  • Amakem NV
  • Digna Biotech, S.L.
  • Lee's Pharmaceutical Holdings Limited

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最新的開發平台資訊

開發暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8146IDB

Summary

Global Markets Direct's, 'Corneal Ulcers - Pipeline Review, H1 2016', provides an overview of the Corneal Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Corneal Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Corneal Ulcers and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Corneal Ulcers
  • The report reviews pipeline therapeutics for Corneal Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Corneal Ulcers therapeutics and enlists all their major and minor projects
  • The report assesses Corneal Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Corneal Ulcers

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Corneal Ulcers
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Corneal Ulcers pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Corneal Ulcers Overview
  • Therapeutics Development
    • Pipeline Products for Corneal Ulcers - Overview
    • Pipeline Products for Corneal Ulcers - Comparative Analysis
  • Corneal Ulcers - Therapeutics under Development by Companies
  • Corneal Ulcers - Therapeutics under Investigation by Universities/Institutes
  • Corneal Ulcers - Pipeline Products Glance
    • Early Stage Products
  • Corneal Ulcers - Products under Development by Companies
  • Corneal Ulcers - Products under Investigation by Universities/Institutes
  • Corneal Ulcers - Companies Involved in Therapeutics Development
    • Amakem NV
    • Digna Biotech, S.L.
    • Lee's Pharmaceutical Holdings Limited
  • Corneal Ulcers - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AMA-0526 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • disitertide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LQ-7 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Parasitic Corneal Ulcers - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZK-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Corneal Ulcers - Recent Pipeline Updates
  • Corneal Ulcers - Dormant Projects
  • Corneal Ulcers - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Corneal Ulcers, H1 2016
  • Number of Products under Development for Corneal Ulcers - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Corneal Ulcers - Pipeline by Amakem NV, H1 2016
  • Corneal Ulcers - Pipeline by Digna Biotech, S.L., H1 2016
  • Corneal Ulcers - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Corneal Ulcers Therapeutics - Recent Pipeline Updates, H1 2016
  • Corneal Ulcers - Dormant Projects, H1 2016
  • Corneal Ulcers - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Corneal Ulcers, H1 2016
  • Number of Products under Development for Corneal Ulcers - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top